Literature DB >> 24380083

Ocular Toxoplasmosis: Controversies in Primary and Secondary Prevention.

Norman A Saffra1, Carly J Seidman1, Louis M Weiss2.   

Abstract

Ocular toxoplasmosis is the most common cause of posterior uveitis in the United States and worldwide. It commonly follows a relapsing course with the potential for multiple adverse visual sequelae and, rarely, blindness. Both immune-competent and immune-suppressed populations can develop severe relapsing disease. There is considerable debate regarding the initial treatment of ocular toxoplasmosis in both groups, with multiple antiparasitic agents commonly used with little evidence to support any particular regimen. The precise role of corticosteroids in treatment also has yet to be rigorously defined. Secondary prevention is commonly implemented in the immune suppressed population, but there is a lack of level one evidence to support its role in immune-competent patients, though it warrants future investigation.

Entities:  

Keywords:  antiparasitic therapy; chemoprophylaxis; infectious retinal disease; ocular toxoplasmosis; retinochoroiditis; secondary prevention

Year:  2013        PMID: 24380083      PMCID: PMC3874278     

Source DB:  PubMed          Journal:  J Neuroinfect Dis


  20 in total

Review 1.  Interventions for toxoplasma retinochoroiditis: a report by the American Academy of Ophthalmology.

Authors:  Stephen J Kim; Ingrid U Scott; Gary C Brown; Melissa M Brown; Allen C Ho; Michael S Ip; Franco M Recchia
Journal:  Ophthalmology       Date:  2012-10-11       Impact factor: 12.079

2.  Prospective randomized trial of trimethoprim/sulfamethoxazole versus pyrimethamine and sulfadiazine in the treatment of ocular toxoplasmosis.

Authors:  Masoud Soheilian; Mohammad-Mehdi Sadoughi; Mehdi Ghajarnia; Mohammad H Dehghan; Shahin Yazdani; Hassan Behboudi; Arash Anisian; Gholam A Peyman
Journal:  Ophthalmology       Date:  2005-09-19       Impact factor: 12.079

3.  Ocular toxoplasmosis: clinical features and prognosis of 154 patients.

Authors:  Lotje E H Bosch-Driessen; Tos T J M Berendschot; Jenny V Ongkosuwito; Aniki Rothova
Journal:  Ophthalmology       Date:  2002-05       Impact factor: 12.079

4.  Annual burden of ocular toxoplasmosis in the US.

Authors:  Jeffrey L Jones; Gary N Holland
Journal:  Am J Trop Med Hyg       Date:  2010-03       Impact factor: 2.345

5.  Value of PCR for detection of Toxoplasma gondii in aqueous humor and blood samples from immunocompetent patients with ocular toxoplasmosis.

Authors:  G Bou; M S Figueroa; P Martí-Belda; E Navas; A Guerrero
Journal:  J Clin Microbiol       Date:  1999-11       Impact factor: 5.948

Review 6.  Toxoplasmosis.

Authors:  J G Montoya; O Liesenfeld
Journal:  Lancet       Date:  2004-06-12       Impact factor: 79.321

7.  [Efficacy of specific chemotherapy in the prevention of recurrences of toxoplasmic chorioretinitis during the 4 years following the treatment].

Authors:  J C Timsit; E Bloch-Michel
Journal:  J Fr Ophtalmol       Date:  1987       Impact factor: 0.818

8.  An update on current practices in the management of ocular toxoplasmosis.

Authors:  Gary N Holland; Kevan G Lewis
Journal:  Am J Ophthalmol       Date:  2002-07       Impact factor: 5.258

9.  Prophylaxis for ocular toxoplasmosis.

Authors:  R Kopec; G De Caro; E Chapnick; M Ghitan; N Saffra
Journal:  Clin Infect Dis       Date:  2003-10-13       Impact factor: 9.079

View more
  5 in total

1.  Rapid resolution of toxoplasma chorioretinitis treatment using quadruple therapy.

Authors:  Arief Kartasasmita; Wendy P Muntur; Sutarya Enus; Erwin Iskandar
Journal:  Clin Ophthalmol       Date:  2017-12-01

2.  A prospective randomized trial of azithromycin versus trimethoprim/sulfamethoxazole in treatment of toxoplasmic retinochoroiditis.

Authors:  Alireza Lashay; Ahmad Mirshahi; Najaf Parandin; Hamid Riazi Esfahani; Mehdi Mazloumi; Mohammad Reza Lashay; Mohammad Karim Johari; Elham Ashrafi
Journal:  J Curr Ophthalmol       Date:  2016-12-28

3.  Intravitreal Clindamycin as First-Line Therapy for Toxoplasmic Retinochoroiditis: A Case Series.

Authors:  Lalit Verma; Mithun Thulasidas; Avnindra Gupta
Journal:  Clin Ophthalmol       Date:  2020-12-07

4.  In Vitro Effect of the Synthetic cal14.1a Conotoxin, Derived from Conus californicus, on the Human Parasite Toxoplasma gondii.

Authors:  Marco A De León-Nava; Eunice Romero-Núñez; Angélica Luna-Nophal; Johanna Bernáldez-Sarabia; Liliana N Sánchez-Campos; Alexei F Licea-Navarro; Jorge Morales-Montor; Saé Muñiz-Hernández
Journal:  Mar Drugs       Date:  2016-04-08       Impact factor: 5.118

Review 5.  Water related ocular diseases.

Authors:  Syed Shoeb Ahmad
Journal:  Saudi J Ophthalmol       Date:  2017-11-04
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.